Drug Trial Radar · NCT03615768
A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Apr 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,617
Actual
Start
Aug 14, 2018
Primary completion
Feb 13, 2020
Study completion Apr 7, 2020
Sponsor
- Lead sponsor
- Lee's Pharmaceutical LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
- First posted
- Aug 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to see if Adapalene-Clindamycin Combination Gel is effective and safe in the treatment of acne vulgaris, compared to adapalene gel alone and clindamycin gel alone. Adapalene and clindamycin have been reported to have a better effect in acne treatment when used together. This new formulation is also easier to use as it combines two products into a single gel and only needs to be used once a day.
Conditions
- Acne Vulgaris
Interventions
Adapalene-Clindamycin Combination GelCombination product
5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
Adapalene GelDrug
Differin 0.1% Gel, applied nightly for 12 weeks
Clindamycin GelDrug
Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Total Lesion CountsTime frame: Week 12
- Proportion of patients who has at least a two-point reduction in Investigator Global Assessment (IGA) compared to baselineTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Dermatology and Hospital for Skin Diseases, Chinese Academy of Medical Sciences
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.